Colfax Corp. (CFX) Announces Philip Okala to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Colfax Corporation (CFX) PT Raised to $53 at Northcoast Research
February 22, 2021 6:33 AM ESTNorthcoast Research analyst Tom Hayes raised the price target on Colfax Corporation (NYSE: CFX) to $53.00 (from $43.00) while maintaining a Buy rating.... More
Colfax Corporation (CFX) PT Raised to $41 at Citi
February 22, 2021 5:22 AM ESTCiti analyst Andrew Kaplowitz raised the price target on Colfax Corporation (NYSE: CFX) to $41.00 (from $35.00) while maintaining a Sell rating.... More
Colfax Corporation (CFX) PT Raised to $55 at JPMorgan, Following Earnings
February 19, 2021 3:12 PM ESTJPMorgan analyst C. Stephen Tusa Jr. raised the price target on Colfax Corporation (NYSE: CFX) to $55.00 (from $52.00) while maintaining a Overweight rating.
... MoreColfax Corporation (CFX) PT Raised to $46 at UBS
February 19, 2021 7:59 AM ESTUBS analyst Chris Snyder raised the price target on Colfax Corporation (NYSE: CFX) to $46.00 (from $45.00) while maintaining a Buy rating.... More
Colfax Corporation (CFX) PT Raised to $41 at Deutsche Bank
February 19, 2021 7:09 AM ESTDeutsche Bank analyst Nicole DeBlase raised the price target on Colfax Corporation (NYSE: CFX) to $41.00 (from $38.00) while maintaining a Hold rating.... More
Colfax Corporation (CFX) PT Raised to $52 at Stifel
February 19, 2021 7:03 AM ESTStifel analyst Nathan Jones raised the price target on Colfax Corporation (NYSE: CFX) to $52.00 (from $50.00) while maintaining a Buy rating.... More
Colfax Corporation (CFX) PT Raised to $53 at BofA Securities
February 19, 2021 6:07 AM ESTBofA Securities analyst Andrew Obin raised the price target on Colfax Corporation (NYSE: CFX) to $53.00 (from $50.00) while maintaining a Buy rating.... More
Colfax Corporation (CFX) PT Raised to $47 at KeyBanc
February 19, 2021 5:04 AM ESTKeyBanc analyst Jeffrey Hammond raised the price target on Colfax Corporation (NYSE: CFX) to $47.00 (from $44.00) while maintaining a Overweight rating.... More
Colfax Corporation (CFX) PT Raised to $40 at Barclays
February 19, 2021 5:04 AM ESTBarclays analyst Julian Mitchell raised the price target on Colfax Corporation (NYSE: CFX) to $40.00 (from $35.00) while maintaining a Equalweight rating.... More
Colfax Corporation (CFX) PT Raised to $46 at UBS
February 19, 2021 4:52 AM ESTUBS analyst Chris Snyder raised the price target on Colfax Corporation (NYSE: CFX) to $46.00 (from $45.00) while maintaining a Neutral rating.... More
Colfax Corporation (CFX) PT Raised to $42 at Morgan Stanley
February 19, 2021 3:18 AM ESTMorgan Stanley analyst Joshua Pokrzywinski raised the price target on Colfax Corporation (NYSE: CFX) to $42.00 (from $39.00) while maintaining a Equalweight rating.... More
UPDATE: Colfax Corp. (CFX) Tops Q4 EPS by 1c, Revenues Miss; Offers FY21 EPS Mid-Point Guidance Above Consensus, 1Q EPS Views Below Consensus
February 18, 2021 6:12 AM EST(Updated - February 18, 2021 6:12 AM EST)
Colfax Corp. (NYSE: CFX) reported Q4 EPS of $0.51, $0.01 better than the analyst estimate of $0.50. Revenue for the quarter came in at $828.12 million versus the consensus estimate of $830.72 million.
Our strong revenue, earnings and cash flow performance demonstrates further recovery in our markets and effective operating execution, said Matt Trerotola, Colfax President and CEO. Customer demand in our Fabrication Technology business strengthened at a faster pace than expected, contributing to strong sales and profit performance. Sales in our MedTech business started the quarter as expected and showed... More
